Cantor Fitzgerald initiated coverage on Catamaran CTRX with a Buy rating and a $56 price target.
Cantor Fitzgerald noted, "The favourable market drivers for the industry include: 1) increased drug utilization; 2) aging population; 3) growth of chronic diseases; and 4) drug price inflation. Catamaran is poised to benefit from the disruption associated with the Express Scripts merger with Medco Health. Major margin drivers for the PBMs are: the increase usage of generic prescription drugs; increased spending on specialty drugs; increased mail and gross margin leverage with scale."
Catamaran closed at $48.56 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in